COVID-19 Update | July 24, 2020

COVID-19 News

COVID-19 Update | July 24, 2020

July 24, 2020

The California Biotechnology Foundation is committed to keeping you up to date about COVID-19 testing, treatment and prevention advancements. The following resources track what progress has been made as of July 24, 2020. Notable advancements include:

  • AstraZeneca and Oxford University’s vaccine showed a robust defense against COVID-19 and move  into Phase III Trials.
  • Pfizer announced a nearly $2 billion contract for 600 million doses of a COVID-19 vaccine, with the first 100 million promised before the end of the year.
  • The National Institutes of Health is preparing to launch large clinical trials to test new approaches to treating COVID-19.

​Recent News:

  • Genentech, other biotechs OK’d to share COVID antibody manufacturing
    San Francisco Business Times – July 23, 2020
    Genentech Inc., Amgen Inc. and other large biotechs received clearance Thursday from the Department of Justice to share know-how around manufacturing facilities and other information that could speed production of potential monoclonal antibody treatments against COVID-19.
  • NIH to start  large studies of potential COVID-19 treatments
    STAT – July 23, 2020
    The National Institutes of Health is preparing to launch large clinical trials to test new approaches to treating COVID-19, hoping to expand what for now remains a limited arsenal of therapies to help people with the disease.

Rely on California Biotechnology Foundation to monitor breaking news and provide updates on the latest advancements in COVID-19 diagnostics, vaccines and treatments.

Stay informed on the latest news and trends on the economic and health benefits of this industry by visiting the new CABiotech.org

If you have any questions about informational briefings contact California Biotechnology Foundation Executive Director Patty Cooper at (916)764-2434 or [email protected].